Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
about
Improving clinical trial design for Duchenne muscular dystrophy.Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy.Reengineering a transmembrane protein to treat muscular dystrophy using exon skippingIdentification of serum protein biomarkers for utrophin based DMD therapy.Translational development of splice-modifying antisense oligomers.N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.
P2860
Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
@ast
Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
@en
type
label
Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
@ast
Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
@en
prefLabel
Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
@ast
Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
@en
P1476
Dystrophin as a therapeutic biomarker: are we ignoring data from the past?
@en
P2093
Steve D Wilton
P304
P356
10.1016/J.NMD.2014.03.007
P577
2014-03-22T00:00:00Z